ArticleFrontiers in pharmacology2022

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial.

Zhichao Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.